AcQBlate Force Confirmatory Study for Atrial Arrhythmias

NCT ID: NCT04429464

Last Updated: 2021-10-20

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-01
• Study Completion Date: 2020-11-15

Brief Summary

AcQBlate Force Confirmatory Study for Atrial Arrhythmias (AcQBlate Force-PRA)

Detailed Description

Acutus Medical's AcQBlate Force Ablation Catheter when used in combination with the Qubic Force Sensing Module (AcQBlate Force System), is indicated for cardiac electrophysiological mapping, delivery of diagnostic pacing stimuli, and radiofrequency ablation of sustained or recurrent atrial arrhythmias.

Conditions

Atrial Arrhythmias

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Non-randomized

All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.

Group Type: EXPERIMENTAL

AcQBlate Force Sensing Ablation Catheter

Intervention Type: DEVICE

Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias

Interventions

AcQBlate Force Sensing Ablation Catheter

Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Male or female between the ages of 18 to 80 years at time of consent.
• Clinically indicated and scheduled for a de novo or repeat catheter ablation of PAF or PerAF
• Willing and able to provide written informed consent to to participate in the study and agree to comply with all follow-up visits and evaluations for the duration of the study.

Exclusion Criteria

• In the opinion of the investigator, any contraindication to the planned atrial ablation, including anticoagulation contraindications or sepsis
• Continuous AF > 12-months (long-standing persistent AF)
• Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause.
• An implanted pacemaker or Implantable Cardiac Defibrillator (ICD).
• Structural heart disease or cardiac history as described below:
• Left ventricular ejection fraction (LVEF) < 35% based on transthoracic echocardiogram (TTE) within the previous 180-days.
• Left atrial size > 55 mm based on TTE within the previous 180-days.
• Evidence of heart failure (NYHA Class III or IV).
• Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for coronary artery bypass).
• Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve.
• Coronary artery bypass graft (CABG) or coronary angioplasty (PTCA) procedure within the last 90-days.
• Unstable angina or ongoing myocardial ischemia.
• Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg, diastolic pressure > 140 mm Hg recorded within the last 30-days.
• Moderate or severe tricuspid stenosis or regurgitation.
• Moderate or severe mitral stenosis or regurgitation.
• Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder.
• Presence of a left atrial appendage occlusion device.
• Previous PV stenting or evidence of PV stenosis
• Body Mass Index (BMI) >40 kg/m2
• History of blood clotting or bleeding disease.
• Any prior history of documented cerebral infarct or systemic embolism (excluding post- operative deep vein thrombosis (DVT)).
• Pregnant or lactating (current or anticipated during study follow up).
• Current enrollment in any other study protocol where testing or results from the study may interfere with the procedure or outcome measurements for this study.
• Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Acutus Medical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Petr Neuzil, MD

Role: PRINCIPAL_INVESTIGATOR

Na Homolce Hospital

Locations

Na Homolce Hospital

Prague, , Czechia

Countries

Czechia

Other Identifiers

CLP-14

Identifier Type: -

Identifier Source: org_study_id